SoundHealth Partners With Vivos Therapeutics to Expand Sleep Tech Access

Vivos Therapeutics Inc. and SoundHealth are teaming up to advance public awareness and access to the latter company’s airway and sleep health technologies.

The collaboration leverages Vivos’ national network of more than 2,000 Vivos-trained dentists and sleep healthcare providers, as well as affiliated sleep testing centers in select markets, to distribute SoundHealth’s Sonu platform, including the U.S. Food and Drug Administration (FDA)-cleared Sonu Band and the newly released Spatial Sleep band. Both devices use personalized vibro-acoustic neuromodulation to harness the body’s natural mechanisms to enable clear nasal breathing and promote deep, restful sleep.

“SoundHealth’s technology across multiple product offerings is perfectly synergistic with Vivos treatment technology,” Vivos Therapeutics CEO Kirk Huntsman commented. “We believe this collaboration will add value-added products to our existing offerings and allow Vivos to maintain its global leadership position in offering sleep, breathing, and now allergy patients the most advanced and effective non-invasive treatments available today for these disorders. Even in our initial rollout, Vivos providers using Sound Health products report high levels of patient satisfaction and are enthusiastic about expanding access and exposure.”

SoundHealth boasts the world’s largest craniofacial dataset for sino-nasal and airway health. The collaboration with Vivos will harness this dataset and SoundHealth’s technology to explore educational and distribution initiatives across Vivos’ large provider network to promote airway health awareness and treatment as a foundational component of sleep and overall wellness, the companies said. Vivos will resell these products across its network; as part of the collaboration, Vivos will have access to SoundHealth’s computed tomography (CT)-accurate smartphone camera-based facial scanning and voice biomarker technology to help clinicians screen, treat, and monitor sleep disorders.

Sonu Band is touted as the world’s first and only FDA-cleared, clinically proven artificial intelligence (AI)-enabled wearable to treat nasal congestion from allergic and non-allergic rhinitis. Named one of TIME’s best inventions last year, the Sonu Band’s efficacy is on par with intranasal steroids, and the product has no side effects. Sonu has also been clinically proven to help CPAP users increase their compliance and adherence.

The Spatial Sleep band’s personalized acoustic resonance therapy has been clinically proven to promote rapid sleep onset and deeper and longer periods of sleep by using active neural entrainment, according to SoundHealth.

Both devices use smartphone front-facing cameras to construct a CT-quality anatomical model of a user’s craniofacial anatomy. This personalized model is then used to generate a customized vibratory therapeutic stimulus. The Sonu smartphone app also pioneers the use of voice biomarkers and facial anatomy to track airway health in real time, helping providers and therapists actively monitor patients.

“Our Sonu platform was built to give people a practical, non-invasive way to help people breathe and sleep using FDA-cleared cutting edge drug free technology,” SoundHealth CEO Paramesh Gopi stated. “This aligns perfectly with Vivos’ mission, and we are excited to collaborate with Vivos to bring our technology and data science to their providers and sleep and airway clinics.”

This focus on airway health addresses urgent medical realities; according to the American Heart Association, untreated sleep-disordered breathing is associated with a 140% increased risk of heart failure and a 30% higher risk of coronary heart disease. Airway health is critical to mitigate these risks at population scale.

“We are witnessing a fundamental shift in the approximately $30 billion global sleep technology sector—moving from passive tracking to active airway interventions. With nearly 80% of sleep-disordered breathing cases currently undiagnosed, the next frontier of health technology isn’t just about monitoring; it is about physically optimizing the airway to treat critical health conditions and improve lives,” Huntsman said.

OSA affects more than 1 billion people worldwide, yet 80% or more remain undiagnosed and unaware of their condition. This chronic disorder is not just a sleep issue—it is closely linked to many serious chronic health conditions. While the medical community has made strides in treating sleep disorders, breathing and sleep health remain areas that are still not fully understood. As a result, legacy OSA treatments like CPAP are often mechanistic and fail to address the root causes of OSA.

SoundHealth is a digital health company striving to improve sinus and sleep health through non-invasive, personalized technology. Its Sonu platform combines wearable devices, intelligent software, and acoustic vibration therapy to help consumers manage nasal congestion and improve sleep quality at home.

Vivos Therapeutics Inc. is a medical technology company developing and commercializing diagnostic and treatment methods for breathing and sleep issues arising from certain dentofacial abnormalities such as obstructive sleep apnea (OSA) and snoring in adults. Vivos’ devices have been cleared by the FDA for adult patients diagnosed with all severity levels of OSA and moderate-to-severe OSA in children ages 6 to 17. Vivos’ Complete Airway Repositioning and Expansion (CARE) devices are the only FDA 510(k)-cleared technology for treating severe OSA in adults and the first to receive clearance for treating moderate to severe OSA in children.

Founded in 2016 and based in Littleton, Colo., Vivos is empowering healthcare providers to address the complex needs of OSA patients more thoroughly. The company calls the use of its appliances and OSA treatment protocols The Vivos Method, which offers a proprietary, clinically effective, nonsurgical, noninvasive, and nonpharmaceutical OSA solution.